Identification of HDM2 as a regulator of VEGF expression in cancer cells

Life Sciences

Volumn 82, Issue 25-26, 2008, Pages 1231-1241

  Narasimhan, Madhusudhanan ^a   Rose, Rajiv ^b   Ramakrishnan, Ramugounder ^a   Zell, Jason A ^c   Rathinavelu, Appu ^a,b  

^a Health Professions Division   (United States)

^b NOVA SOUTHEASTERN UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hdm2 + VEGF; VEGF + GI 101A; VEGF + HL 60; VEGF + HUVEC; VEGF expression

Indexed keywords

DIETHYLSTILBESTROL; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PHORBOL DIBUTYRATE; PROTEIN MDM2; VASCULOTROPIN;

ANGIOGENESIS; ANTISENSE THERAPY; ARTICLE; CANCER CELL; CELL STRAIN HL 60; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; UMBILICAL VEIN;

COCULTURE TECHNIQUES; CULTURE MEDIA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HL-60 CELLS; HUMANS; MIDDLE AGED; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-MDM2; RNA, MESSENGER; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 44649112375     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2008.04.004     Document Type: Article

References (54)

1. Bárdos J.I., Chau N.-M., and Ashcroft M. Growth factor-mediated induction of HDM2 positively regulates hypoxia-inducible factor 1α expression. Molecular and Cellular Biology 24 (2004) 2905-2914
2. Bates D.O., Cui T.G., Doughty J.M., Winkler M., Sugiono M., Shields J.D., Peat D., Gillatt D., and Harper S.J. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Research 62 (2002) 4123-4131
3. Borgstrom P., Killan K.J., Sriramarao P., and Ferrara N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital video microscopy. Cancer Research 56 (1996) 4032-4039
4. Borgstrom P., Gold D.P., Hillan K.J., and Ferrara N. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Research 19 (1999) 4203-4214
5. Breier G., Albrecht U., Sterrer S., and Risau W. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development (Cambridge, England) 114 (1992) 521-532
6. Bueso-Ramos C.E., Manshouri T.M., Haidar M.A., Yang Y., McCown P., Ordonez N., Glassman A., Sneige N., and Albitar M. Abnormal expression of MDM-2 in breast carcinonams. Breast Cancer Research and Treatment 37 (1996) 179-188
7. 165-189 ratio results in a significant enhancement of human prostrate tumor angiogenesis. International Journal of Cancer 120 (2007) 2096-2109
8. Chen L., Agarwal S., Zhou W., Zhang R., and Chen J. Synergistic activation of p53 by inhibition of mdm2 expression and DNA damage. Proceedings of the National Academy of Sciences of the United States of America 95 (1998) 195-200
9. DeFouw L.M., and DeFouw D.O. Protein kinase C activity contributes to endothelial hyperpermeability during early angiogenesis in the chick chorioallantoic membrane. Tissue & Cell 33 (2001) 135-140
10. Dubs-Poterszman M.C., Tocque B., and Wasylyk B. MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest. Oncogene 11 (1995) 2445-2449
11. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. Journal of Molecular Medicine 77 (1999) 527-543
12. Ferrara N., and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocrine Reviews 18 (1997) 4-25
13. Finkenzeller G., Sparacio A., Technau A., Marme D., and Siemeister G. Sp1 recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression. Oncogene 15 (1997) 669-676
14. Folkman J. What is the evidence that tumors are angiogenesis dependent?. Journal of the National Cancer Institute 82 (1990) 4-6
15. Fontanini G., Boldrini L., Vignati S., Chine S., Basolo F., Silvestri V., Lucchi M., Mussi A., Angeletti C.A., and Bevilacqua G. Bcl-2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung carcinoma. European Journal of Cancer 34 (1998) 718-723
16. Frum R., Busby S.A., Ramamoorthy M., Deb S., Shabanowitz J., Hunt D.F., and Deb S.P. HDM2-binding partners: interaction with translation elongation factor EF1alpha. Journal of Proteome Research 6 4 (2007) 1410-1417
17. Ganguli G., and Wasylyk B. P53-independent functions of MDM2. Molecular Cancer Research 1 (2003) 1027-1035
18. Gerwins P., Skoldenberg E., and Claesson-Welsh L. Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis. Critical Reviews in Oncology/Hematology 34 (2000) 185-194
19. Gille J., Swerlick R.A., and Caughman S.W. Transforming growth factor-α-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation. The EMBO Journal 16 (1997) 750-759
20. Gu L., Findley H.W., and Zhou M. MDM2 induces NF-kB/p65 expression transcriptionally through Sp1-binding sites: a novel, p53-independent role of MDM2 in doxorubicin resistance in acute lymphoblastic leukemia. Blood 99 (2002) 3367-3375
21. Herr F., Liang O.D., Herrero J., Lang U., Preissner K.T., Han V.K.M., and Zygmunt M. Possible angiogenic roles of insulin-like growth factor II and its receptors in uterine vascular adaptation to pregnancy. The Journal of Clinical Endocrinology and Metabolism 88 (2003) 4811-4817
22. Hsieh J.K., Chan F.S., O'Connor D.J., Mittnacht S., Zhong S., and Lu X. RB regulates the stability and the apoptotic function of p53 via MDM2. Molecular Cell 3 (1999) 181-193
23. Houck K.A., Ferrara N., Winer J., Cachianes G., Li B., and Leung D.W. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Molecular Endocrinology 5 (1991) 1806-1814
24. Jingjing L., Xue Y., Agarwal N., and Roque R.S. Human Muller cells express VEGF183, a novel spliced variant of vascular endothelial growth factor. Investigative Ophthalmology & Visual Science 40 (1999) 752-759
25. Kieser A., Weich H.A., Brandner G., Marme D., and Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 9 (1994) 963-969
26. Korff T., and Augustin H.G. Tensional forces in fibrillar extracellular matrices control directional capillary sprouting. Journal of Cell Science 112 Pt 19 (1999) 3249-3258
27. Lange T., Guttmann-Raviv N., Baruch L., Machluf M., and Neufeld G. VEGF162, a new heparin-binding vascular endothelial growth factor splice form that is expressed in transformed human cells. The Journal of Biological Chemistry 278 (2003) 17164-17169
28. LaRusch G.A., Jackson M.W., Dunbar J.D., Warren R.S., Donner D.B., and Mayo L.D. Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1 alpha and Hdm2. Cancer Research 67 2 (2007) 450-454
29. Leng P., Brown D.R., Shivakumar C.V., Deb S., and Deb S.P. N-terminal 130 amino acids of MDM2 are sufficient to inhibit p53-mediated transcriptional activation. Oncogene 10 (1995) 1275-1282
30. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., and Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246 (1989) 1306-1309
31. Linderholm B.K., Lindahl T., Holmberg L., Klaar S., Lennerstrand J., Henriksson R., and Bergh J. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Research 61 (2001) 2256-2260
32. Martin K., Trouche D., Hagemeier C., Sorensen T.S., La Thangue N.B., and Kouzarides T. Stimulation of E2F1/Dp1 transcriptional activity by MDM-2 oncoprotein. Nature 375 (1995) 691-694
33. Matsumoto R., Tada M., Nozaki M., Zhang C.L., Sawamura Y., and Abe H. Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms. Cancer Research 58 (1998) 609-613
34. Moreira I.S., Fernandes P.A., and Ramos M.J. Vascular endothelial growth factor (VEGF) inhibition - a critical review. Anti-cancer Agents in Medicinal Chemistry 7 2 (2007) 223-245
35. Na X., Wu G., Ryan C.K., Schoen S.R., di'Santagnese P.A., and Messing E.M. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. The Journal of Urology 170 2 Pt 1 (2003) 588-592
36. Narasimhan M., Rose R., Karthikeyan M., and Rathinavelu A. Detection of HDM2 and VEGF co-expression in cancer cell lines: novel effect of HDM2 antisense treatment on VEGF expression. Life Sciences 81 (2007) 1362-1372
37. Narendran A., Ganjavi H., Morson N., Connor A., Barlow J.W., Keystone E., Malkin D., and Freedman M.H. Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth. Experimental Hematology 31 (2003) 693-701
38. Neufeld G., Cohen T., Gitay-Goren H., Poltorak Z., Tessler S., Sharon R., Gengrinovitch S., and Levi B. Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants. Cancer Metastasis Reviews 15 (1996) 153-158
39. Poltorak Z., Cohen T., Sivan R., Kandelis Y., Spira G., Vlodavsky I., Keshet E., and Neufeld G. VEGF 145 a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. The Journal of Biological Chemistry 272 (1997) 7151-7158
40. Pore N., Liu S., Haas-Kogan D.A., O'Rourke D.M., and Maity A. PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter. Cancer Research 63 (2003) 236-241
41. Ramakrishnan R., Zell J.A., Malave A., and Rathinavelu A. Expression of vascular endothelial growth factor mRNA in GI-101A and HL-60 cell lines. Biochemical and Biophysical Research Communications 270 (2000) 709-713
42. Rathinavelu P., Malave A., Raney S.R., Hurst J., Roberson C.T., and Rathinavelu A. Expression of mdm-2 oncoprotein in the primary and metastatic sites of mammary tumor (GI-101) implanted athymic nude mice. Cancer Biochemistry Biophysics 17 1-2 (1999) 133-146
43. Ryuto M., Ono M., Izumi H., Yoshida S., Weich H.A., Kohno K., and Kuwano M. Induction of vascular endothelial growth factor by tumor necrosis factor in human glioma cells. Possible roles of SP-1. The Journal of Biological Chemistry 271 (1996) 28220-28228
44. Shibuya M., Ito N., and Claesson-Welsh L. Structure and function of vascular endothelial growth factor receptor-1 and -2. Current Topics in Microbiology and Immunology 237 (1999) 59-83
45. Strous G.J., and Schantl J.A. β-arrestin and Mdm2, unsuspected partners in signaling from the cell surface. Science's STKE: Signal Transduction Knowledge Environment 110 (2001) PE41
46. Tischer E., Mitchell R., Hartman T., Silva M., Gospodarowicz D., Fiddes J.C., and Abraham J.A. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. The Journal of Biological Chemistry 266 (1991) 11947-11954
47. Van Meir E.G., Polverini P.J., Chazin V.R., Su Huang H.J., de Tribolet N., and Cavenee W.K. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nature Genetics 8 (1994) 171-176
48. Van Noorden C.J.F., Meade-Tollin L.C., and Bosmanm F.T. Metastasis: the spread of cancer cells to distant sites implies a complex series of cellular abnormalities caused, in part, by genetic aberrations. American Scientist 86 (1998) 130-141
49. Wei D., Wang L., He Y., Xiong H.Q., Abbruzzese J.L., and Xie K. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Research 64 (2004) 2030-2038
50. Whittle C., Gillespie K., Harrison R., Mathieson P.W., and Harper S.J. Heterogeneous vascular endothelial growth factor (VEGF) isoform mRNA and receptor mRNA expression in human glomeruli, and the identification of VEGF148 mRNA, a novel truncated splice variant. Clinical Science (London, England: 1979) 97 (1999) 303-312
51. Xiao Z., Chen J., Levine A.J., Modjtahedi N., Xing J., Sellers W.R., and Livingston D.M. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375 (1995) 694-698
52. Yamamura M., Uyemura K., Deans R.J., Weinberg K., Rea T.H., Bloom B.R., and Modlin R.L. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science 254 (1991) 277-279
53. Yogosawa S., Miyauchi Y., Honda R., Tanaka H., and Yasuda H. Mammalian Numb is a target protein of Mdm2, ubiquitin ligase. Biochemical and Biophysical Research Communications 302 (2003) 869-872
54. Yoshiji H., Gomez D.E., Shibuya M., and Thorgeirsson U.P. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Research 56 (1996) 2013-2016